ConductScience.org, home

Paper39589586

Advances in irreversible electroporation for prostate cancer.

Liu X and 9 others. Discov Oncol, 2024. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Advances in irreversible electroporation for prostate cancer. Papers, record 39589586. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39589586

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Advances in irreversible electroporation for prostate cancer.
PubMed
Journal
Discov Oncol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.82, provisional
iCite
Revised in PubMed
2024-11-30
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu XXinyu
2Wang HHao
3Zhao ZZilin
4Zhong QQikai
5Wang XXinlei
6Liu XXing
7Chen JJunzhi
8Han CConghui
9Shi ZZhenduo
10Liang QQing

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
2023YFC2413403National Key Research and Development Program of ChinaPubMed
82004110National Natural Science Foundation of ChinaPubMed
K2023041Key project of Jiangsu Provincial Health CommissionPubMed
MS2023081General Program State Administration of Traditional Chinese Medicine of JiangsuPubMed

Source PubMed

Download CSV of grants

References123

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136216618Impact of margin accentuation with intraoperative irreversible electroporation on local recurrence in resected pancreatic cancer.Surgery2023https://conductscience.org/library/papers/36216618PubMed
227393627Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma.J Surg Oncol2016https://conductscience.org/library/papers/27393627PubMed
336901812Irreversible Electroporation in Pancreatic Cancer-An Evolving Experimental and Clinical Method.Int J Mol Sci2023https://conductscience.org/library/papers/36901812PubMed
436073928Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years.J Urol2023https://conductscience.org/library/papers/36073928PubMed
532488359Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).World J Urol2021https://conductscience.org/library/papers/32488359PubMed
630986263Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.PLoS One2019https://conductscience.org/library/papers/30986263PubMed
729075594Irreversible electroporation of stage 3 locally advanced pancreatic cancer: optimal technique and outcomes.J Vis Surg2015https://conductscience.org/library/papers/29075594PubMed
835044426Experimental and Numerical Investigation of Parameters Affecting High-Frequency Irreversible Electroporation for Prostate Cancer Ablation.J Biomech Eng2022https://conductscience.org/library/papers/35044426PubMed
939080139Irreversible Electroporation Margin Accentuation in Pancreaticoduodenectomy: A Propensity Score Matching Analysis.Ann Surg Oncol2024https://conductscience.org/library/papers/39080139PubMed
1029594551Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy.World J Urol2018https://conductscience.org/library/papers/29594551PubMed
1131069281An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements.APL Bioeng2017https://conductscience.org/library/papers/31069281PubMed
1229102671Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation.Eur Urol Focus2019https://conductscience.org/library/papers/29102671PubMed
1338513683
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial.
Lancet Gastroenterol Hepatol2024https://conductscience.org/library/papers/38513683PubMed
1435793110Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial.JAMA Surg2022https://conductscience.org/library/papers/35793110PubMed
1531971335
Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry.
BJU Int2020https://conductscience.org/library/papers/31971335PubMed
1632423258Mathematical modeling of the thermal effects of irreversible electroporation for in vitro, in vivo, and clinical use: a systematic review.Int J Hyperthermia2020https://conductscience.org/library/papers/32423258PubMed
1731161973Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.Radiology2019https://conductscience.org/library/papers/31161973PubMed
1824589913Comparison of the effects of the repetition rate between microsecond and nanosecond pulses: electropermeabilization-induced electro-desensitization?Biochim Biophys Acta2014https://conductscience.org/library/papers/24589913PubMed
1936687122Irreversible electroporation for the management of pancreatic cancer: Current data and future directions.World J Gastroenterol2023https://conductscience.org/library/papers/36687122PubMed
2034349171Effects of high-frequency nanosecond pulses on prostate cancer cells.Sci Rep2021https://conductscience.org/library/papers/34349171PubMed

See all 123 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
41908232Irreversible electroporation for localized prostate cancer: risk-stratified oncologic outcomes and functional preservation.Prostate Int2026https://conductscience.org/library/papers/41908232PubMed
41357174Pulsed electric fields: a sharp sword in the battle against cancers.Front Immunol2025https://conductscience.org/library/papers/41357174PubMed
41132360Optilume drug-coated balloon dilation for treatment of post-prostate cancer ablative therapy urethral stricture: a case series.Transl Androl Urol2025https://conductscience.org/library/papers/41132360PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39589586

GET https://conductscience.org/api/papers/v1/39589586/references?page=2